InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,360.80
(
-0.94%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.66
(
0.15%
)
Bitcoin
65,805.56
(
0.03%
)
Post# of 43137
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonDonDonDon

Send PM Follow Ignore
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

DonDonDonDon

Re: ohm20 post# 33374

Monday, 09/13/2021 4:13:49 PM

Monday, September 13, 2021 4:13:49 PM

Post# of 43137

The NIH would not be violating their own protocol. "Unofficially" excluding patients would make the trial invalid.


If they are still treating patients with CRP>150mg/L or >85yo, it isn't a big deal. They represented about 25% of the LIVE-AIR trial. Still seems strange that they'd treat patients that aren't part of the primary endpoint. Maybe they had to keep the inclusion criteria the same in order to not start a new trial. This way they can look at the patients with CRP<150mg/L and <85yo from the whole ACTIV-5 as one patient population.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up